Athersys to Present at 2017 Cell & Gene Meeting on the Mesa and Announces Regenerative Medicine Advanced Therapy (RMAT) Desig...
October 05 2017 - 7:00AM
Athersys, Inc. (NASDAQ:ATHX) announced today that Robert W. Mays,
Ph.D., Vice President, Regenerative Medicine and Head of
Neuroscience Programs, will present at the annual Partnering Forum
as part of the Cell & Gene Meeting on the Mesa to be held
October 4-6 in La Jolla, California.
Dr. Mays will provide a brief overview of the
Company’s neuroscience programs, focusing on the Phase 3 clinical
program for ischemic stroke, which previously received special
Protocol Assessment (SPA) and Fast Track designations from the U.S.
Food and Drug Administration (FDA), and recently obtained a Final
Scientific Advice positive opinion from the European Medicines
Agency.
The Company is also pleased to announce that it
has received the Regenerative Medicine Advanced Therapy (RMAT)
designation from the FDA, recently established under the 21st
Century Cures Legislation. The RMAT designation may be
obtained for eligible cell therapy and other regenerative medicine
and advanced therapies when the FDA agrees that preliminary
clinical evidence indicates that the therapy has demonstrated the
potential to address unmet medical needs for a serious or life
threatening disease or condition. The designation enables sponsors
to discuss with the FDA multidisciplinary strategic development
plans, including expediting manufacturing development plans for
commercialization to support priority review and accelerated
approval.
The following are specific details regarding
Athersys’ presentation at the conference:
Event: |
|
2017 Cell & Gene
Meeting on the Mesa – Partnering Forum |
|
|
|
Date: |
|
October 5, 2017 |
|
|
|
Time: |
|
4:30 – 4:45 pm Pacific
Time |
|
|
|
Location: |
|
La Jolla Ballroom 1 at
the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines
Road, La Jolla, CA 92037 |
This conference is the largest partnering
meeting organized specifically for the cell and gene therapy
sector, providing the opportunity for participants to establish key
relationships and accelerate business development. Organized
by ARM and the Sanford Stem Cell Clinical Center at UC San Diego,
the Cell & Gene Meeting on the Mesa is a three-day conference
featuring three distinct parts, the program’s two-day Partnering
Forum, a Public Forum lecture and a full-day Scientific Symposium.
The event’s Partnering Forum on October 4-5, features more than 70
dedicated company presentations in addition to 90 panelists and
featured speakers.
A live video webcast of all company
presentations will be available at:
http://www.meetingonthemesa.com/webcast/ and will also be published
on ARM’s website shortly after the event. Please visit
www.meetingonthemesa.com for full information including
registration. Complimentary attendance at this event is available
for credentialed investors and members of the media only. Investors
should contact Laura Parsons at lparsons@alliancerm.org and
interested media should contact Lyndsey Scull at
lscull@alliancerm.org.
About Athersys
Athersys is an international biotechnology
company engaged in the development of therapeutic products designed
to extend and enhance the quality of human life. The Company is
developing its MultiStem® cell therapy product, a patented,
adult-derived "off-the-shelf" stem cell product, initially for
disease indications in the neurological, cardiovascular, and
inflammatory and immune disease areas, and has several ongoing
clinical trials evaluating this potential regenerative medicine
product. Athersys has forged strategic partnerships and a broad
network of collaborations to further advance MultiStem cell therapy
toward commercialization. More information is available at
www.athersys.com. Follow Athersys on Twitter at
www.twitter.com/athersys.
ATHX-G
Contact:William (B.J.) LehmannPresident and
Chief Operating OfficerTel: (216)
431-9900bjlehmann@athersys.com
Karen HunadyCorporate CommunicationsTel: (216)
431-9900khunady@athersys.com
David SchullRusso Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024